Skip to content

Vitamin D Supplementation and Tibia Fracture. Does it Improve Healing Rate?

Vitamin D Supplementation in Patients With Operated Tibia Fracture and Low Vitamin D. Does it Improve Healing Rate?. Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03232216
Acronym
ViDco
Enrollment
682
Registered
2017-07-27
Start date
2017-11-21
Completion date
2023-08-18
Last updated
2017-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture Healing, Tibial Fractures, Vitamin D Deficiency

Brief summary

This study evaluates the effect of Vitamin D3 supplementation in healing rate of tibia fractures in adult patients with low vitamin D. Half of participants will receive Vitamin D3 supplementation while the other will receive placebo.

Interventions

DIETARY_SUPPLEMENTVitamin D3.

Vitamin D3 50.000 UI in each packet of powder for oral solution.

DIETARY_SUPPLEMENTPlacebo

Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.

Sponsors

Hospital del Trabajador de Santiago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

* Tibial fracture * ASA physical status classification system I-II. * 25 hydroxyvitamin D below 30ng/ml) * Fracture treatment with reamed intramedullary nail

Exclusion criteria

* Open Fractures Gustillo III B and III C * Closed Soft tissue injury with Tscherne classification of III * Acute Compartment Syndrome * Pathology fractures (That occur in abnormal bone, for example in the presence of tumor, cyst or Paget disease) * Other Fractures in lower limbs or spine that does not allow full weight bearing of the operated tibia after 4 weeks * More than 7 days of evolution from fracture occurrence * Diabetes mellitus with HbA1c more or equal than 7% * Peripheral vascular disease * Rickets * Pre-existing disorders of the metabolism of Vitamin D and/or homeostasis of calcium and phosphorous (ie. Hepatic insufficiency, congenital defects of the vitamin D metabolism, disorders of the parathyroid glands, hypo or hyper calcemia) * Renal failure with glomerular filtration rate below 60ml/min according to MDRD-4. * Patients using nephrotoxic medications in high doses, requiring periodical monitoring of glomerular filtration rate * Patients undergoing with nephrotic syndrome or that suffered it in the past * Patients that suffered nephrolithiasis or urolithiasis * Pregnant women * Patients with allergy to vitamin D or other contraindications for vitamin D3 prescription * Patients that are taking multivitamin supplements containing vitamin D and will not suspend taking them during the study. * Patients that are not able to swallow a cup of water

Design outcomes

Primary

MeasureTime frameDescription
Fracture non union2 yearsRate of fracture non union in each group

Secondary

MeasureTime frameDescription
Prevalence of low vitamin D in adults with tibia fracture10 daysUsing the first measurement of 25 hydroxyvitamin D
Time of fracture healing2 yearsTime that lasted consolidation, from surgery
Short Form 36 score (SF-36)2 yearsHealth associated quality of life
EuroQol five dimensions questionnaire (EQ-5D)2 yearsGeneric health status measurement
Knee Range of movement2 yearsKnee flexion and extension in degrees
Ankle Range of movement2 yearsAnkle flexion and extension in degrees
Superficial Infections2 yearsIncidence of superficial infections in each group
Deep infections2 yearsIncidence of superficial infections in each group
Visual Analogue Scale (VAS)2 yearsPain measurement using VAS

Countries

Chile

Contacts

Primary ContactSebastian Drago, MD
sdrago@hts.cl+56992191310
Backup ContactJose Rojas, MD
josemrojasf@gmail.com+56991671221

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026